Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03178552 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Name: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) — clinical trial record (NCT03178552)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: B-FAST

StatusActive, Not Recruiting

PhasePhase 2/3

SponsorHoffmann-La Roche

Started2017-09-22

View on ClinicalTrials.gov ↗

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.

Amendment history 3 changes detected by DataLookout

2026-09-04

Trial sites reduced: 164 → 161 locations

2026-09-04

Primary completion pushed: 2026-10-31 → 2027-06-30

2026-09-04

Completion pushed: 2026-10-31 → 2027-06-30

Trial Details

NCT Number	NCT03178552
Lead Sponsor	Hoffmann-La Roche
Conditions	Non-Small Cell Lung Cancer
Enrollment	1,000 participants
Start Date	2017-09-22
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-03